Adlai Nortye Ltd. ADS/$ANL

1D1W1MYTD1Y5YMAX

About Adlai Nortye Ltd. ADS

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Ticker
$ANL
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Singapore, Singapore
Website
www.adlainortye.com

ANL Metrics

BasicAdvanced
$999M
-
-$0.56
1.12
-

Bulls say / Bears say

Strong balance sheet bolstered by $231.9 million in cash and short-term investments as of June 30, 2026, up from $8.1 million at December 31, 2025, providing over a year of operational runway. (Adlai Nortye IR)
Robust investor backing demonstrated by two oversubscribed private placements in February and April 2026, raising $140 million and $150 million respectively, evidencing strong market confidence in the pipeline. (Adlai Nortye IR)
Regulatory progress achieved with Human Research Ethics Committee approval in Australia in July 2026 for the Phase I trial of AN4035, marking the first regulatory go-ahead for its ADC program and de-risking development. (Adlai Nortye Form 6-K)
Extended development timelines delay value inflection points, with initial clinical data for AN9025 not expected until 1H 2027 and AN4035 data anticipated in 2H 2027, prolonging binary risk and value realization. (Adlai Nortye IR)
Significant dilution risk arises from a mixed shelf registration filed in April 2026 for up to $600 million of ADSs, which could materially dilute existing shareholders if fully drawn. (MarketScreener)
Limited revenue diversity evident in H1 2026, where $13.1 million in revenue was solely derived from upfront and milestone payments under a single license agreement, underscoring dependence on future milestone achievements for ongoing cash flow. (Adlai Nortye IR)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.